BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 2,450,284 shares of Minerva Neurosciences Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 2,450,284 shares of Minerva Neurosciences Inc. common stock.
  • Percent of class: The reported stake represents 5.1% of the outstanding common shares.
  • Sole voting power: BlackRock disclosed sole voting power over 2,410,935 shares.
  • Sole dispositive power: BlackRock disclosed sole dispositive power over 2,450,284 shares.
  • Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
  • Triggering date: The date of the event requiring the filing was September 30, 2026.
  • Filer classification: BlackRock is classified as a parent holding company (type HC), incorporated in Delaware.

BlackRock's Schedule 13G Disclosure on Minerva Neurosciences Common Stock

According to the filing, BlackRock, Inc., headquartered at 50 Hudson Yards, New York, NY 10001, submitted a Schedule 13G reporting its beneficial ownership position in Minerva Neurosciences Inc. (CUSIP 603380205), whose principal executive offices are located at 1500 District Avenue, Burlington, MA 01803. The filing was signed by Spencer Fleming, Managing Director, on October 27, 2026, with an event date of September 30, 2026.

The filing states that the Schedule 13G "reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates." The filing further notes that it "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units" in accordance with SEC Release No. 34-39538 (January 12, 1998). The identity and classification of the relevant subsidiaries are provided in Exhibit 99 attached to the filing.

Regarding dividends and disposition proceeds, the filing discloses that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of MINERVA NEUROSCIENCES INC." It also states that "no one person's interest in the common stock of MINERVA NEUROSCIENCES INC is more than five percent of the total outstanding common shares." BlackRock certified that the securities were acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Minerva Neurosciences.

What Was Disclosed

BlackRock, Inc. filed a Schedule 13G disclosing beneficial ownership of 2,450,284 shares, or 5.1%, of Minerva Neurosciences Inc. common stock as of September 30, 2026, with sole voting power over 2,410,935 shares and sole dispositive power over the full 2,450,284 shares.